{"id":"bay94-9027","safety":{"commonSideEffects":[{"rate":null,"effect":"Inhibitor development (factor VIII antibodies)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL2109629","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BAY94-9027 is a recombinant human coagulation factor VIII conjugated with polyethylene glycol (PEG), which increases its circulating half-life compared to conventional factor VIII products. This extended half-life allows for less frequent dosing while maintaining therapeutic factor VIII levels, improving convenience and compliance in hemophilia A management. The drug functions as a direct replacement of the deficient clotting factor in the intrinsic coagulation pathway.","oneSentence":"BAY94-9027 is a long-acting factor VIII replacement therapy that extends the half-life of clotting factor VIII through PEGylation, reducing dosing frequency in hemophilia A patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:11.113Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A (routine prophylaxis and treatment of bleeding episodes)"}]},"trialDetails":[{"nctId":"NCT06940830","phase":"PHASE4","title":"Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-05-21","conditions":"Hemophilia A","enrollment":250},{"nctId":"NCT04293523","phase":"","title":"A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-03-30","conditions":"Hemophilia A","enrollment":427},{"nctId":"NCT06224907","phase":"PHASE3","title":"Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2023-12-25","conditions":"Hemophilia A","enrollment":6},{"nctId":"NCT03588299","phase":"PHASE1, PHASE2","title":"Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a \"Shuttle\"","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2018-11-07","conditions":"Hemophilia A","enrollment":11},{"nctId":"NCT07088458","phase":"","title":"An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-04-30","conditions":"Hemophilia A","enrollment":40},{"nctId":"NCT06998524","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-27","conditions":"Von Willebrand Disease, Type 3","enrollment":75},{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":"Von Willebrand Disease, Type 3","enrollment":40},{"nctId":"NCT06111638","phase":"PHASE2, PHASE3","title":"Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs","status":"RECRUITING","sponsor":"Shanghai Xinzhi BioMed Co., Ltd.","startDate":"2024-01-03","conditions":"Hemophilia A","enrollment":55},{"nctId":"NCT07416526","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-05-09","conditions":"Hemophilia A","enrollment":126},{"nctId":"NCT07032792","phase":"PHASE2","title":"Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-11-03","conditions":"Cardiac Disease, Surgery, Bleeding","enrollment":140},{"nctId":"NCT03932201","phase":"","title":"Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2019-10-21","conditions":"Hemophilia A","enrollment":371},{"nctId":"NCT04461639","phase":"","title":"Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-05-14","conditions":"Hemophilia A","enrollment":62},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT07439055","phase":"PHASE2, PHASE3","title":"Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chulalongkorn University","startDate":"2025-06-01","conditions":"Hemophilia A Patient","enrollment":18},{"nctId":"NCT05568719","phase":"PHASE3","title":"Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-28","conditions":"Hemophilia A, Hemophilia B","enrollment":173},{"nctId":"NCT04953884","phase":"PHASE3","title":"Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age","status":"COMPLETED","sponsor":"Octapharma","startDate":"2021-09-22","conditions":"Von Willebrand Disease","enrollment":12},{"nctId":"NCT04158934","phase":"","title":"A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2020-07-09","conditions":"Hemophilia A","enrollment":207},{"nctId":"NCT04563520","phase":"PHASE3","title":"SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT06579144","phase":"PHASE1","title":"Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-02-24","conditions":"Hemophilia A","enrollment":24},{"nctId":"NCT07414511","phase":"","title":"Hemophilia A Research Program","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-31","conditions":"Hemophilia A, Hemophilia A, Severe, Factor VIII (FVIII)","enrollment":500},{"nctId":"NCT05932914","phase":"","title":"Liver Biopsy Following Gene Therapy For Hemophilia","status":"NOT_YET_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03","conditions":"Hemophilia A, Hemophilia B","enrollment":8},{"nctId":"NCT06574984","phase":"","title":"Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-11-10","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":900},{"nctId":"NCT07410130","phase":"","title":"Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03","conditions":"Von Willebrand Disease (VWD), Inherited Bleeding Disorders in Children, Pediatric Hemostatic Disorders","enrollment":25},{"nctId":"NCT07400848","phase":"","title":"Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome","status":"RECRUITING","sponsor":"University of Bern","startDate":"2026-02-15","conditions":"Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue","enrollment":200},{"nctId":"NCT05145127","phase":"PHASE3","title":"Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-11-17","conditions":"Hemophilia A, Hemophilia B","enrollment":245},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT04431726","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-04","conditions":"Severe Hemophilia A","enrollment":55},{"nctId":"NCT06716814","phase":"PHASE3","title":"Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-03-06","conditions":"Severe Haemophilia A","enrollment":104},{"nctId":"NCT05181618","phase":"PHASE4","title":"A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-20","conditions":"Severe Hemophilia A, Moderate Hemophilia A","enrollment":136},{"nctId":"NCT04158648","phase":"PHASE3","title":"A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-10","conditions":"Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A","enrollment":73},{"nctId":"NCT05147662","phase":"PHASE3","title":"A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-03-23","conditions":"Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A","enrollment":36},{"nctId":"NCT06222697","phase":"","title":"A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-01-24","conditions":"Hemophilia A, Prophylaxis of Bleeding, Treatment of Bleeding","enrollment":20},{"nctId":"NCT05022459","phase":"","title":"Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2023-08-16","conditions":"Hemophilia A","enrollment":72},{"nctId":"NCT05936580","phase":"PHASE4","title":"Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery","status":"RECRUITING","sponsor":"Octapharma","startDate":"2026-04","conditions":"Hemophilia A","enrollment":28},{"nctId":"NCT05768386","phase":"","title":"A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)","status":"ENROLLING_BY_INVITATION","sponsor":"BioMarin Pharmaceutical","startDate":"2023-01-01","conditions":"Hemophilia A","enrollment":172},{"nctId":"NCT07129343","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-10-13","conditions":"Von Willebrand Disease (VWD)","enrollment":20},{"nctId":"NCT06738485","phase":"PHASE3","title":"Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-01-09","conditions":"Congenital Hemophilia A","enrollment":60},{"nctId":"NCT07314983","phase":"","title":"Long-term Anticoagulation in a Patient With Severe Hemophilia A","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-09-22","conditions":"Hemophilia A","enrollment":1},{"nctId":"NCT04204408","phase":"PHASE2","title":"A Research Study Investigating Mim8 in People With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-10","conditions":"Healthy Volunteers, Haemophilia A With or Without Inhibitors","enrollment":275},{"nctId":"NCT06752850","phase":"PHASE4","title":"A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2024-12-19","conditions":"Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia","enrollment":37},{"nctId":"NCT04146376","phase":"","title":"Von Willebrand Factor in Pregnancy (VIP) Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2019-10-12","conditions":"Von Willebrand Diseases","enrollment":110},{"nctId":"NCT03754790","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2019-01-09","conditions":"Hemophilia","enrollment":281},{"nctId":"NCT03818763","phase":"PHASE1","title":"Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2020-04-29","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT05036278","phase":"PHASE4","title":"Prophylaxis Regimen for Hemophilia A Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-07-28","conditions":"Hemophilia A, Prophylaxis of Bleeding","enrollment":21},{"nctId":"NCT03695978","phase":"","title":"Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients","status":"RECRUITING","sponsor":"Octapharma","startDate":"2018-02-13","conditions":"Haemophilia A","enrollment":200},{"nctId":"NCT03587116","phase":"PHASE3","title":"A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-26","conditions":"Hemophilia B, Hemophilia A","enrollment":212},{"nctId":"NCT05935358","phase":"PHASE4","title":"Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study","status":"RECRUITING","sponsor":"Octapharma","startDate":"2023-11-28","conditions":"Severe Hemophilia A","enrollment":28},{"nctId":"NCT02941783","phase":"","title":"Drug Use Investigation of Kovaltry in Hemophilia A Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Hemophilia A","enrollment":230},{"nctId":"NCT05582993","phase":"PHASE3","title":"A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-06","conditions":"Von Willebrand Disease (VWD)","enrollment":24},{"nctId":"NCT05817812","phase":"PHASE3","title":"A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2023-07-31","conditions":"Hemophilia A, Severe","enrollment":93},{"nctId":"NCT04323098","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2020-12-08","conditions":"Hemophilia A","enrollment":22},{"nctId":"NCT06684314","phase":"","title":"A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-11","conditions":"Hemophilia A","enrollment":100},{"nctId":"NCT05042440","phase":"PHASE1","title":"Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-08-11","conditions":"Hemophilia A","enrollment":13},{"nctId":"NCT04161495","phase":"PHASE3","title":"A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2019-11-19","conditions":"Factor VIII Deficiency","enrollment":159},{"nctId":"NCT04759131","phase":"PHASE3","title":"Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2021-02-19","conditions":"Hemophilia A","enrollment":74},{"nctId":"NCT03370172","phase":"PHASE1, PHASE2","title":"A Study of BAX 888 in Male Adults With Severe Hemophilia A","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-02-27","conditions":"Hemophilia A","enrollment":4},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT03879135","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2019-04-01","conditions":"Von Willebrand Disease (VWD)","enrollment":38},{"nctId":"NCT05643560","phase":"","title":"An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2022-12-29","conditions":"Hemophilia A, Prophylaxis of Bleeding","enrollment":33},{"nctId":"NCT03520712","phase":"PHASE1, PHASE2","title":"Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5","status":"TERMINATED","sponsor":"BioMarin Pharmaceutical","startDate":"2018-04-24","conditions":"Hemophilia A, Gene Therapy, Clotting Disorders","enrollment":3},{"nctId":"NCT06339567","phase":"NA","title":"Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2024-02-08","conditions":"Polycystic Ovary Syndrome","enrollment":352},{"nctId":"NCT04370054","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-08-18","conditions":"Hemophilia A","enrollment":77},{"nctId":"NCT06273865","phase":"","title":"Version Testing of EnzySystem Version A for Hemophilia A","status":"SUSPENDED","sponsor":"Radboud University Medical Center","startDate":"2024-05-29","conditions":"Hemophilia A","enrollment":40},{"nctId":"NCT05611801","phase":"PHASE3","title":"A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-09","conditions":"Hemophilia A, Hemophilia B","enrollment":100},{"nctId":"NCT06550882","phase":"","title":"A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-07-22","conditions":"Acquired Hemophilia A","enrollment":9},{"nctId":"NCT04728841","phase":"NA","title":"Gene Therapy for Chinese Hemophilia A","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-03-04","conditions":"Hemophilia A, Gene Therapy","enrollment":12},{"nctId":"NCT04644575","phase":"PHASE3","title":"Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bioverativ, a Sanofi company","startDate":"2021-02-23","conditions":"Hemophilia A","enrollment":261},{"nctId":"NCT02615691","phase":"PHASE3","title":"A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-11-12","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT04684940","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2020-12-10","conditions":"Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII","enrollment":10},{"nctId":"NCT05695391","phase":"PHASE3","title":"A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM","status":"TERMINATED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2024-06-07","conditions":"Hemophilia","enrollment":2},{"nctId":"NCT04091386","phase":"","title":"Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-06-10","conditions":"Hemophilia A","enrollment":10},{"nctId":"NCT00868530","phase":"PHASE3","title":"Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Hemophilia A","enrollment":53},{"nctId":"NCT03938792","phase":"PHASE3","title":"Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-03-09","conditions":"Hemophilia A, Hemophilia B","enrollment":189},{"nctId":"NCT05437211","phase":"NA","title":"A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-06-23","conditions":"Hemophilia","enrollment":24},{"nctId":"NCT06461533","phase":"","title":"A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-06-10","conditions":"Acquired Hemophilia A","enrollment":25},{"nctId":"NCT05707351","phase":"PHASE3","title":"A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-03-27","conditions":"Hemophilia A","enrollment":37},{"nctId":"NCT02932618","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)","status":"RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2017-11-06","conditions":"Von Willebrand Disease","enrollment":31},{"nctId":"NCT06938659","phase":"PHASE2, PHASE3","title":"Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients","status":"NOT_YET_RECRUITING","sponsor":"Dhaka Medical College","startDate":"2025-06-01","conditions":"Hemophilia A","enrollment":20},{"nctId":"NCT04565236","phase":"PHASE4","title":"A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-09-22","conditions":"Hemophilia A","enrollment":45},{"nctId":"NCT02576795","phase":"PHASE1, PHASE2","title":"Gene Therapy Study in Severe Haemophilia A Patients (270-201)","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2015-09-28","conditions":"Severe Haemophilia A","enrollment":15},{"nctId":"NCT03370913","phase":"PHASE3","title":"Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2017-12-19","conditions":"Hemophilia A","enrollment":144},{"nctId":"NCT06864975","phase":"PHASE4","title":"Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)","status":"RECRUITING","sponsor":"Runhui WU","startDate":"2025-03-01","conditions":"Hemophilia a with Inhibitor","enrollment":110},{"nctId":"NCT03001830","phase":"PHASE1, PHASE2","title":"Gene Therapy for Haemophilia A.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2017-06-14","conditions":"Hemophilia A","enrollment":14},{"nctId":"NCT04690322","phase":"PHASE4","title":"POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-04-15","conditions":"Hemophilia A, Factor VIII","enrollment":28},{"nctId":"NCT05454774","phase":"EARLY_PHASE1","title":"A Study of FVIII Gene Therapy for Hemophilia A","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-07-19","conditions":"Hemophilia A","enrollment":8},{"nctId":"NCT05523128","phase":"NA","title":"The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-09-29","conditions":"Hemophilia A","enrollment":6},{"nctId":"NCT04046848","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A","status":"TERMINATED","sponsor":"Octapharma","startDate":"2019-07-03","conditions":"Severe Hemophilia A","enrollment":36},{"nctId":"NCT03169972","phase":"","title":"ADYNOVATE Drug Use-Results Survey","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-01","conditions":"Hemophilia A","enrollment":135},{"nctId":"NCT00323856","phase":"PHASE4","title":"Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A","status":"COMPLETED","sponsor":"Grifols Biologicals, LLC","startDate":"2003-04-08","conditions":"Severe Hemophilia A","enrollment":51},{"nctId":"NCT04675541","phase":"","title":"Register of Patients With haEmophilia A tReated With Afstyla®","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2018-09-24","conditions":"Haemophilia A","enrollment":62},{"nctId":"NCT03003533","phase":"PHASE1, PHASE2","title":"A Gene Transfer Study for Hemophilia A","status":"COMPLETED","sponsor":"Spark Therapeutics, Inc.","startDate":"2017-01-26","conditions":"Hemophilia A","enrollment":25},{"nctId":"NCT02460458","phase":"","title":"Type 3 Von Willebrand International Registries Inhibitor Prospective Study","status":"COMPLETED","sponsor":"Fondazione Angelo Bianchi Bonomi","startDate":"2012-11-05","conditions":"Type 3 Von Willebrand's Disease","enrollment":265},{"nctId":"NCT06205095","phase":"PHASE3","title":"A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD","status":"RECRUITING","sponsor":"Unity Health Toronto","startDate":"2024-10-21","conditions":"Von Willebrand Diseases","enrollment":20},{"nctId":"NCT02207894","phase":"","title":"A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI","status":"RECRUITING","sponsor":"Haemophilia Centre Rhine Main","startDate":"2006-08","conditions":"Haemophilia A","enrollment":300},{"nctId":"NCT06738901","phase":"PHASE3","title":"An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients","status":"NOT_YET_RECRUITING","sponsor":"SK Plasma Co., Ltd.","startDate":"2025-03-31","conditions":"Hemophilia A, Severe","enrollment":55},{"nctId":"NCT06297486","phase":"PHASE3","title":"Study of a Gene Therapy Treatment for Hemophilia A","status":"WITHDRAWN","sponsor":"Spark Therapeutics, Inc.","startDate":"2024-03-13","conditions":"Hemophilia A","enrollment":""},{"nctId":"NCT04555785","phase":"PHASE4","title":"Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-04-01","conditions":"Bleeding","enrollment":120},{"nctId":"NCT04580407","phase":"PHASE2, PHASE3","title":"Study of TAK-672 in Participants With Acquired Hemophilia A","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-04-09","conditions":"Acquired Hemophilia A","enrollment":5},{"nctId":"NCT04941898","phase":"","title":"A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-06-30","conditions":"Hemophilia A","enrollment":16},{"nctId":"NCT02976753","phase":"","title":"Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2016-12","conditions":"Hemophilia A","enrollment":361}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BAY94-9027","genericName":"BAY94-9027","companyName":"Bayer","companyId":"bayer","modality":"Biologic","firstApprovalDate":"","aiSummary":"BAY94-9027 is a long-acting factor VIII replacement therapy that extends the half-life of clotting factor VIII through PEGylation, reducing dosing frequency in hemophilia A patients. Used for Hemophilia A (routine prophylaxis and treatment of bleeding episodes).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}